XL 784

Drug Profile

XL 784

Alternative Names: XL784

Latest Information Update: 17 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action ADAM10 protein inhibitors; Angiogenesis inhibitors; Matrix metalloproteinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Diabetic nephropathies

Most Recent Events

  • 18 Jan 2008 GlaxoSmithKline decides not to exercise its option to license XL 784
  • 07 Nov 2007 Final results from a Phase-II clinical trial in patients with Diabetic nephropathies added to the adverse events and Diabetes therapeutic trials sections
  • 16 Oct 2007 Exelixis completes a Phase-II trial in Diabetic nephropathies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top